Cargando…

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease

OBJECTIVE: To assess the cost-effectiveness of 3 treatments (tiotropium, salmeterol, and no treatment) in patients with moderate chronic obstructive pulmonary disease (COPD). METHODS: A Markov model with a time horizon of 1 year was developed. A hypothetical cohort of 100,000 subjects with moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Shalini, Kamal, Khalid M, Keys, Patricia A, Mattei, Thomas J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169962/
https://www.ncbi.nlm.nih.gov/pubmed/21935312
_version_ 1782211556868620288
author Naik, Shalini
Kamal, Khalid M
Keys, Patricia A
Mattei, Thomas J
author_facet Naik, Shalini
Kamal, Khalid M
Keys, Patricia A
Mattei, Thomas J
author_sort Naik, Shalini
collection PubMed
description OBJECTIVE: To assess the cost-effectiveness of 3 treatments (tiotropium, salmeterol, and no treatment) in patients with moderate chronic obstructive pulmonary disease (COPD). METHODS: A Markov model with a time horizon of 1 year was developed. A hypothetical cohort of 100,000 subjects with moderate COPD with mean age of 65 years, smoking history of 50 pack-years, and disease duration of 9.5 years were included in the model. The efficacy and withdrawal data were taken from published randomized clinical trials. The effectiveness measure was exacerbations avoided per patient per year. Incremental cost-effectiveness ratio (ICER) was calculated as additional cost per patient to prevent 1 exacerbation, compared with the next most expensive option. A payer’s perspective was used and only direct costs were included in the study. Sensitivity analyses were conducted to test the robustness of the baseline estimates and study assumptions. RESULTS: The mean annual costs for the no treatment, salmeterol, and tiotropium groups were $392.1, $1268.7, and $1408.6, respectively. The ICER of tiotropium compared with no treatment was $1817.36 per exacerbation avoided, while the ICER of salmeterol compared with no treatment was $2454.48 per exacerbation avoided. Thus, in patients with moderate COPD, tiotropium is more cost-effective than salmeterol and no treatment.
format Online
Article
Text
id pubmed-3169962
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31699622011-09-20 Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease Naik, Shalini Kamal, Khalid M Keys, Patricia A Mattei, Thomas J Clinicoecon Outcomes Res Original Research OBJECTIVE: To assess the cost-effectiveness of 3 treatments (tiotropium, salmeterol, and no treatment) in patients with moderate chronic obstructive pulmonary disease (COPD). METHODS: A Markov model with a time horizon of 1 year was developed. A hypothetical cohort of 100,000 subjects with moderate COPD with mean age of 65 years, smoking history of 50 pack-years, and disease duration of 9.5 years were included in the model. The efficacy and withdrawal data were taken from published randomized clinical trials. The effectiveness measure was exacerbations avoided per patient per year. Incremental cost-effectiveness ratio (ICER) was calculated as additional cost per patient to prevent 1 exacerbation, compared with the next most expensive option. A payer’s perspective was used and only direct costs were included in the study. Sensitivity analyses were conducted to test the robustness of the baseline estimates and study assumptions. RESULTS: The mean annual costs for the no treatment, salmeterol, and tiotropium groups were $392.1, $1268.7, and $1408.6, respectively. The ICER of tiotropium compared with no treatment was $1817.36 per exacerbation avoided, while the ICER of salmeterol compared with no treatment was $2454.48 per exacerbation avoided. Thus, in patients with moderate COPD, tiotropium is more cost-effective than salmeterol and no treatment. Dove Medical Press 2010-03-09 /pmc/articles/PMC3169962/ /pubmed/21935312 Text en © 2010 Naik et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Naik, Shalini
Kamal, Khalid M
Keys, Patricia A
Mattei, Thomas J
Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
title Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
title_full Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
title_fullStr Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
title_full_unstemmed Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
title_short Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
title_sort evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169962/
https://www.ncbi.nlm.nih.gov/pubmed/21935312
work_keys_str_mv AT naikshalini evaluatingthecosteffectivenessoftiotropiumversussalmeterolinthetreatmentofchronicobstructivepulmonarydisease
AT kamalkhalidm evaluatingthecosteffectivenessoftiotropiumversussalmeterolinthetreatmentofchronicobstructivepulmonarydisease
AT keyspatriciaa evaluatingthecosteffectivenessoftiotropiumversussalmeterolinthetreatmentofchronicobstructivepulmonarydisease
AT matteithomasj evaluatingthecosteffectivenessoftiotropiumversussalmeterolinthetreatmentofchronicobstructivepulmonarydisease